Globus Medical fell 12.8% after earnings, as investors likely focused on near-flat total revenue, only 2% U.S. Spine growth, and delayed product launches and production issues that management said are limiting growth until 2027. Nevro’s 25.7% decline added to the drag, despite growth in enabling technologies and higher EPS.
Shares declined 12.6% as investors reacted negatively to a cautious revenue mix shift and softer growth in Enabling Technologies, signaling concerns over decelerating upfront sales and a more conservative capital equipment approach.
Globus Medical reported a robust Q3 2025, with sales increasing 22.9% to $769 million and non-GAAP EPS jumping 42.6% to $1.18, driven by strong growth in both the U.S. and international spine markets.